DOCSLIB.ORG

High Risk Therapy Made Easy: Supporting High Risk Patients Through Complex Therapy

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
High Risk Therapy Made Easy: Supporting High Risk Patients Through Complex Therapy 8/21/2018 High Risk Therapy Made Easy: Supporting high risk patients through complex therapy Lori Ranney, MSN, APRN, CPNP, CPHON Mylynda Livingston, MSN, APRN, AC PC-PNP, CPON Teresa Herriage, DNP, APRN, CPNP, CPHON Children’s Minnesota Disclaimers and Confidentiality Protections Children’s Minnesota makes no representations or warranties about the accuracy, reliability, or completeness of the content. Content is provided “as is” and is for informational use only. It is not a substitute for professional medical advice, diagnosis, or treatment. Children’s disclaims all warranties, express or implied, statutory or otherwise, including without limitation the implied warranties of merchantability, non-infringement of third parties’ rights, and fitness for a particular purpose. This content was developed for use in Children’s patient care environment and may not be suitable for use in other patient care environments. Children’s does not endorse, certify, or assess third parties’ competency. You hold all responsibility for your use or nonuse of the content. Children’s shall not be liable for claims, losses, or damages arising from or related to any use or misuse of the content. This content and its related discussions are privileged and confidential under Minnesota’s peer review statute (Minn. Stat. § 145.61 et. seq.). Do not disclose unless appropriately authorized. Notwithstanding the foregoing, content may be subject to copyright or trademark law; use of such information requires Children’s permission. This content may include patient protected health information. You agree to comply with all applicable state and federal laws protecting patient privacy and security including the Minnesota Health Records Act and the Health Insurance Portability and Accountability Act and its implementing regulations as amended from time to time. Please ask if you have any questions about these disclaimers and/or confidentiality protections. © 2018 2 Speaker Disclosure Statement o Lori Ranney has no industry relationships to disclose. o Mylynda Livingston has no industry relationships to disclose. o Teresa Herriage has no industry relationships to disclose. © 2018 3 1 8/21/2018 Objectives: • Learner will be able to identify strategies to support patients undergoing immunotherapy drugs; blinatumomab and dinutuximab • Learner will be able to identify high risk (HR) patients that would benefit from upfront infection prophylaxis based on risk factors © 2018 4 New Therapies for ALL Blinatumomab (BLINCYTO) received FDA approval for children with relapsed or refractory ALL in 2016. BLINCYTO is a bispecific CD19-directed CD3 T cell engager (BiTE®) antibody construct that binds specifically to CD19 expressed on the surface of cells of B-lineage origin and CD3 expressed on the surface of T cells. © 2018 5 © 2018 6 2 8/21/2018 Lessons Learned from Early Blinatumomab Studies Evidence of clinical activity and benefit Very short half-life: 2 hours − Required continuous exposure for clinical benefit Results in T cell Activation: − T cell proliferation − Lysis of tumor cells − Cytokine release Development of AALL1331: Blinatumomab with UKALLR3 backbone © 2018 7 Blinatumomab administration Blinatumomab is a 28 day continuous IV infusion. IV bag will be changed every 96 hours •Hospitalization: Hospitalization is STRONGLY recommended during the first 9 days of the first blinatumomab cycle and the first 2 days of subsequent blinatumomab cycles in case of a cytokine reaction (from package insert for Blincyto) Premedication: Dexamethasone − Day 1: 6-12 hours prior to initiation of infusion − Day 1: 30 minutes prior to infusion Blinatumomab infusion should not be interrupted for LP procedures © 2018 8 Administration – continued Avoid Interruptions − Any interruption >1 hour should be recorded Any interruptions >4 hours requires readmission to hospital to resume − A new bag of Blinatumomab should be prepared when resuming after >4 hour interruption − Additional dexamethasone pre-medication For interruptions due to line issues the infusion should be switched to the other lumen to re-start as fast as possible. © 2018 9 3 8/21/2018 Administration Pearls Avoid flushing the dedicated Blinatumomab line − Can result in a bolus dose of Blinatumomab − Bolus dose less concerning on AALL1331 compared to early phase trials (reduced tumor burden) Avoid flushing with IV Blinatumomab bag changes Some flushing is unavoidable! − End of 28 day infusion − Unblocking CVL occlusions − Hospital policies © 2018 10 Adverse Events from Blinatumomab Most common AEs: central and peripheral neurotoxicity and cytokine release syndrome (CRS) All neurotoxicity is reversible © 2018 11 Cytokine Release Syndrome Constellation of inflammatory symptoms Results from cytokine elevations Associated with T cell proliferation CRS ranges from mild to severe to life threatening Mild: flu-like symptoms, fever, myalgia Severe: vascular leak, hypotension, pulmonary edema, coagulopathy Life threatening: can lead to multi-system organ failure Cytokine elevations can be measured Degree of elevation does not always correlate to clinical severity © 2018 12 4 8/21/2018 Management of CRS Reported with first cycle of Blini, typically within first 12- 72 hours Most Significantly elevated Cytokines: IL10, IL6, IFNy Is it possible to target the Cytokines themselves? Anti IL6 (tocilizumab) – resolution of CRS Reversal and clinical improvement seen within 24 hours Maude, Journal of Cancer, 2014; Barrett, Current Opinions in Pediatrics, 2014 © 2018 13 Case Study - Noah • Diagnosed 12/30/08 at age 3 with pre B ALL • Completed therapy on 4/22/12 • Routine off therapy long-term follow-up visit reveals relapse in peripheral blood on 4/22/16 • Flow on relapse marrow shows + CD 10, CD19, CD22, CD34, CD 52, CD 79a, TdT • Enrolled on relapse study COG AALL1331 • End of Block I marrow shows MRD 10.2% • Determination by COG of Intermediate Risk and randomized to receive arm of study with Blinatumomab © 2018 14 Noah (cont.) • Cycle 1 of Blinatumomab started on 6/7/16 • Did well with only mild neurological side effects as well as fever for 24 hours after drug started – all resolved within 36 hours • End of Cycle 1 (Block II) MRD (after 28 days of Blinatumomab) is negative! • Proceeds per study Cycle 2 (28 more days of Blinatumomab) • No signs of CRS or neurological toxicity • Proceeds to 6/6 umbilical cord blood transplant at U of MN Sept 2016. • Doing well now 24 months post transplant. © 2018 15 5 8/21/2018 Exciting News! Blincyto approved September 2016 for pediatric ALL patients. Photo taken from http://www.blincyto.com/blincyto-blinatumomab/mechanism-of-action/ © 2018 16 The Future of Blinatumomab •Use in off study pediatric patients •Bridging therapy for MRD positive patients to prep for transplant •Single agent versus in combination with other chemotherapy backbones © 2018 17 Case Study - Bryan •Presented at age 9 on 9/23/15 with WBC 600,000 and diagnosed with PH + ALL. •Received 4 drug Induction per COG AALL1131 with addition of dasatinib. •CHG with IKAROS •Day 29 marrow MRD 0.01. Fish + for BCR/ABL at 0.2%. •Follow up marrow after 2 cycles of Consolidation is negative (MRD and FISH) © 2018 18 6 8/21/2018 Bryan (cont.) •CNS (3b) and Bone Marrow relapse 3/13/17. •Received TACL Carfilzomib study (Carfilzomib, dex, dauno, PEG, Vinc. •Marrow shows 25% blasts, 75% BCR/ABL positivity by FISH, and 61% positivity for IKAROS •Salvage therapy consisted of cytoxan/etoposide (5 days) and nilotinib (30 days). •Marrow with 4.6% blasts, 5% BCR-ABL postivity by FISH. © 2018 19 Case Study - Brian •Transplant 7/31 with umbilical cord •Died 9/12 from infectious complications from transplant. © 2018 20 © 2018 21 7 8/21/2018 Neuroblastoma ● Small round blue cell tumor ● Arises from neural crest cells (nerve tissue) ● Arises from adrenal gland or paraspinal sympathetic nerves. ● Most common extra cranial tumor of childhood ● More than half have high risk disease ● Cause is unknown ● ALK gene described in 2008 © 2018 22 Incidence of Neuroblastoma ● Males more than females ● 8% of all childhood cancer ● 15% of childhood cancer deaths ● 40% - under 1 year ● Most diagnosed under 5 years of age (~90%) ● Familial ● Most cause is unknown © 2018 23 Treatment High Risk ● Standard of Care (~18 months) ● NMTRC012 − 6 cycles of induction chemotherapy − Surgical resection after 4 or 5 cycles − Molecular Guided Therapy at start of cycle 3 ● Autologous HSCT − Busulfan/Melphalan • Less toxicity then CEM ● Radiation therapy (standard or proton beam) − Primary site, plus boost to remaining MIBG + sites ● MRD therapy − Dinutuximab − 3F8 ● Maintenance − 2 years DFMO © 2018 24 8 8/21/2018 MRD therapy Dinutuximab with IL-2/GMCSF Most have problems with refractory microscopic residual disease ANBL0032 started in October 2001 Stopped randomization with median follow-up of 2.1 yrs after randomization, event free survival was significantly higher for patients randomized to immunotherapy, with 2- yr estimates of 66%+5% vs 46%+5% Post radiation and within 200 days post BMT Immunotherapy targets a tumor associated antigen, GD2. Highly expressed on NBL cells. Some expression on normal cells 6 courses (courses 1, 3 uses GM-CSF for ADCC and 2, 4 uses IL-2) Each course has 2 weeks of oral retinoic acid following admission © 2018 25 Dinutuximab with IL-2/GMCSF ● Most have problems with refractory microscopic residual disease ● ANBL0032 started in October 2001 ● Post radiation and within 200 days post BMT ● Immunotherapy targets a tumor associated antigen, GD2. ● 6 courses (alternate
Load more

Recommended publications
  • Monoclonal Antibody: a New Treatment Strategy Against Multiple Myeloma
    antibodies Review Monoclonal Antibody: A New Treatment Strategy against Multiple Myeloma Shih-Feng Cho 1,2,3, Liang Lin 3, Lijie Xing 3,4, Tengteng Yu 3, Kenneth Wen 3, Kenneth C. Anderson 3 and Yu-Tzu Tai 3,* 1 Division of Hematology & Oncology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung 807, Taiwan; [email protected] 2 Faculty of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan 3 LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA; [email protected] (L.L.); [email protected] (L.X.); [email protected] (T.Y.); [email protected] (K.W.); [email protected] (K.C.A.) 4 Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong University, No. 324, Jingwu Road, Jinan 250021, China * Correspondence: [email protected]; Tel.: +1-617-632-3875; Fax: +1-617-632-2140 Received: 20 October 2017; Accepted: 10 November 2017; Published: 14 November 2017 Abstract: 2015 was a groundbreaking year for the multiple myeloma community partly due to the breakthrough approval of the first two monoclonal antibodies in the treatment for patients with relapsed and refractory disease. Despite early disappointments, monoclonal antibodies targeting CD38 (daratumumab) and signaling lymphocytic activation molecule F7 (SLAMF7) (elotuzumab) have become available for patients with multiple myeloma in the same year. Specifically, phase 3 clinical trials of combination therapies incorporating daratumumab or elotuzumab indicate both efficacy and a very favorable toxicity profile. These therapeutic monoclonal antibodies for multiple myeloma can kill target cells via antibody-dependent cell-mediated cytotoxicity, complement-dependent cytotoxicity, and antibody-dependent phagocytosis, as well as by direct blockade of signaling cascades.
    [Show full text]
  • Pharmacologic Considerations in the Disposition of Antibodies and Antibody-Drug Conjugates in Preclinical Models and in Patients
    antibodies Review Pharmacologic Considerations in the Disposition of Antibodies and Antibody-Drug Conjugates in Preclinical Models and in Patients Andrew T. Lucas 1,2,3,*, Ryan Robinson 3, Allison N. Schorzman 2, Joseph A. Piscitelli 1, Juan F. Razo 1 and William C. Zamboni 1,2,3 1 University of North Carolina (UNC), Eshelman School of Pharmacy, Chapel Hill, NC 27599, USA; [email protected] (J.A.P.); [email protected] (J.F.R.); [email protected] (W.C.Z.) 2 Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; [email protected] 3 Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; [email protected] * Correspondence: [email protected]; Tel.: +1-919-966-5242; Fax: +1-919-966-5863 Received: 30 November 2018; Accepted: 22 December 2018; Published: 1 January 2019 Abstract: The rapid advancement in the development of therapeutic proteins, including monoclonal antibodies (mAbs) and antibody-drug conjugates (ADCs), has created a novel mechanism to selectively deliver highly potent cytotoxic agents in the treatment of cancer. These agents provide numerous benefits compared to traditional small molecule drugs, though their clinical use still requires optimization. The pharmacology of mAbs/ADCs is complex and because ADCs are comprised of multiple components, individual agent characteristics and patient variables can affect their disposition. To further improve the clinical use and rational development of these agents, it is imperative to comprehend the complex mechanisms employed by antibody-based agents in traversing numerous biological barriers and how agent/patient factors affect tumor delivery, toxicities, efficacy, and ultimately, biodistribution.
    [Show full text]
  • Dinutuximab for the Treatment of Pediatric Patients with High-Risk Neuroblastoma
    Expert Review of Clinical Pharmacology ISSN: 1751-2433 (Print) 1751-2441 (Online) Journal homepage: http://www.tandfonline.com/loi/ierj20 Dinutuximab for the treatment of pediatric patients with high-risk neuroblastoma Jaume Mora To cite this article: Jaume Mora (2016): Dinutuximab for the treatment of pediatric patients with high-risk neuroblastoma, Expert Review of Clinical Pharmacology, DOI: 10.1586/17512433.2016.1160775 To link to this article: http://dx.doi.org/10.1586/17512433.2016.1160775 Accepted author version posted online: 02 Mar 2016. Published online: 21 Mar 2016. Submit your article to this journal Article views: 21 View related articles View Crossmark data Full Terms & Conditions of access and use can be found at http://www.tandfonline.com/action/journalInformation?journalCode=ierj20 Download by: [Hospital Sant Joan de Deu], [Jaume Mora] Date: 30 March 2016, At: 23:12 EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2016 http://dx.doi.org/10.1586/17512433.2016.1160775 DRUG PROFILE Dinutuximab for the treatment of pediatric patients with high-risk neuroblastoma Jaume Mora Department of Pediatric Onco-Hematology and Developmental Tumor Biology Laboratory, Hospital Sant Joan de Déu, Passeig Sant Joan de Déu, Barcelona, Spain ABSTRACT ARTICLE HISTORY Neuroblastoma (NB) is the most common extra cranial solid tumor of childhood, with 60% of patients Received 14 December 2015 presenting with high risk (HR) NB by means of clinical, pathological and biological features. The 5-year Accepted 29 February 2016 survival rate for HR-NB remains below 40%, with the majority of patients suffering relapse from Published online chemorefractory tumor. Immunotherapy is the main strategy against minimal residual disease and 21 March 2016 clinical experience has mostly focused on monoclonal antibodies (MoAb) against the glycolipid dis- KEYWORDS ialoganglioside GD2.
    [Show full text]
  • Blincyto Pi Hcp English.Pdf
    HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use BLINCYTO® safely and effectively. See full prescribing information for BLINCYTO. - Premedicate with dexamethasone. (2.2) BLINCYTO® (blinatumomab) for injection, for intravenous use • Refer to Full Prescribing Information for important preparation and Initial U.S. Approval: 2014 administration information. (2.4, 2.5, 2.6) • Administer as a continuous intravenous infusion at a constant flow rate using an infusion pump. (2.5, 2.6) WARNING: CYTOKINE RELEASE SYNDROME and - See Section 2.5 for infusion over 24 hours or 48 hours. NEUROLOGICAL TOXICITIES - See Section 2.6 for infusion over 7 days using Bacteriostatic 0.9% See full prescribing information for complete boxed warning. Sodium Chloride Injection, USP (containing 0.9% benzyl alcohol). This option is not recommended for patients weighing less than 22 kg. • Cytokine Release Syndrome (CRS), which may be life-threatening or fatal, occurred in patients receiving BLINCYTO. Interrupt or ---------------------DOSAGE FORMS AND STRENGTHS---------------------- discontinue BLINCYTO and treat with corticosteroids as For injection: 35 mcg of lyophilized powder in a single-dose vial for recommended. (2.3, 5.1) reconstitution. (3) • Neurological toxicities, which may be severe, life-threatening, or fatal, occurred in patients receiving BLINCYTO. Interrupt or discontinue -------------------------------CONTRAINDICATIONS------------------------------ BLINCYTO as recommended. (2.3, 5.2) Known hypersensitivity
    [Show full text]
  • The Potential of Adoptive Transfer of Γ9δ2 T Cells to Enhance
    www.nature.com/scientificreports OPEN The potential of adoptive transfer of γ9δ2 T cells to enhance blinatumomab’s antitumor activity against B‑cell malignancy Yun‑Hsiang Chen1, Yun Wang2, Cheng‑Hao Liao3 & Shu‑Ching Hsu4,5,6,7,8,9* Blinatumomab, a bispecifc T cell engager (BiTE) antibody targeting CD19 and CD3ε, can redirect T cells toward CD19‑positive tumor cells and has been approved to treat relapsed/refractory B‑cell acute lymphoblastic leukemia (R/R B‑ALL). However, chemotherapeutic regimens can severely reduce T cells’ number and cytotoxic function, leading to an inadequate response to blinatumomab treatment in patients. In addition, it was reported that a substantial portion of R/R B‑ALL patients failing blinatumomab treatment had the extramedullary disease, indicating the poor ability of blinatumomab in treating extramedullary disease. In this study, we investigated whether the adoptive transfer of ex vivo expanded γ9δ2 T cells could act as the efector of blinatumomab to enhance blinatumomab’s antitumor activity against B‑cell malignancies in vivo. Repeated infusion of blinatumomab and human γ9δ2 T cells led to more prolonged survival than that of blinatumomab or human γ9δ2 T cells alone in the mice xenografted with Raji cells. Furthermore, adoptive transfer of γ9δ2 T cells reduced tumor mass outside the bone marrow, indicating the potential of γ9δ2 T cells to eradicate the extramedullary disease. Our results suggest that the addition of γ9δ2 T cells to the blinatumomab treatment regimens could be an efective approach to enhancing blinatumomab’s therapeutic efcacy. The concept of this strategy may also be applied to other antigen‑specifc BiTE therapies for other malignancies.
    [Show full text]
  • Federal Register Notice 5-1-2020 Pdf Icon[PDF – 358
    Federal Register / Vol. 85, No. 85 / Friday, May 1, 2020 / Notices 25439 confidential by the respondent (5 U.S.C. schedules. Other than examination DEPARTMENT OF HEALTH AND 552(b)(4)). reports, it provides the only financial HUMAN SERVICES Current actions: The Board has data available for these corporations. temporarily revised the instructions to The Federal Reserve is solely Centers for Disease Control and the FR Y–9C report to accurately reflect responsible for authorizing, supervising, Prevention the revised definition of ‘‘savings and assigning ratings to Edges. The [CDC–2020–0046; NIOSH–233–C] deposits’’ in accordance with the Federal Reserve uses the data collected amendments to Regulation D in the on the FR 2886b to identify present and Hazardous Drugs: Draft NIOSH List of interim final rule published on April 28, potential problems and monitor and Hazardous Drugs in Healthcare 2020 (85 FR 23445). Specifically, the develop a better understanding of Settings, 2020; Procedures; and Risk Board has temporarily revised the activities within the industry. Management Information instructions on the FR Y–9C, Schedule HC–E, items 1(b), 1(c), 2(c) and glossary Legal authorization and AGENCY: Centers for Disease Control and content to remove the transfer or confidentiality: Sections 25 and 25A of Prevention, HHS. withdrawal limit. As a result of the the Federal Reserve Act authorize the ACTION: Notice and request for comment. revision, if a depository institution Federal Reserve to collect the FR 2886b chooses to suspend enforcement of the (12 U.S.C. 602, 625). The obligation to SUMMARY: The National Institute for six transfer limit on a ‘‘savings deposit,’’ report this information is mandatory.
    [Show full text]
  • And Grand Overview
    Welcome and Grand Overview Rose Aurigemma, PhD Acting Associate Director, Developmental Therapeutics Program Division of Cancer Treatment & Diagnosis, NCI July 23, 2021 Thank You to the Organizing Committee Weiwei Chen, Program Director, PTGB, DTP Rachelle Salomon, Program Director, BRB, DTP Sharad Verma, Program Director, PTGB, DTP Jason Yovandich, Chief, BRB, DTP Sundar Venkatachalam, Chief, PTGB, DTP 2 Introduction to the Developmental Therapeutics Program In 1955, congress created the Cancer Chemotherapy National Service Center which evolved, both structurally and functionally, into today’s Developmental Therapeutics Program (DTP). DTP’s involvement in the discovery or development of many anticancer therapeutics on the market today demonstrates its indelible impact on efforts to improve the health and well-being of people with cancer. 3 Approved Cancer Therapies with DTP Assistance 2018 Moxetumomab pasudotox-tdfk 1983 Etoposide (NSC 141540) 2015 Dinutuximab (Unituxin, NSC 764038) 1982 Streptozotocin (NSC 85998) Ecteinascidin 743 (NSC 648766) 1979 Daunorubicin (NSC 82151) 2012 Omacetaxine (homoharringtonine, NSC 141633) 1978 Cisplatin (cis-platinum) (NSC 119875) 2010 Eribulin (NSC 707389) 1977 Carmustine (BCNU) (NSC 409962) Sipuleucel-T (NSC 720270) 1976 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosurea (CCNU) 2009 Romidepsin (NSC 630176) (NSC 9037) Pralatrexate (NSC 713204) 1975 Dacarbazine (NSC 45388) 2004 Azacitidine (NSC 102816) 1974 Doxorubicin (NSC 123127) Cetuximab (NSC 632307) Mitomycin C (NSC 26980) 2003 Bortezomib (NSC 681239) 1973
    [Show full text]
  • Update in Pediatric Oncology Pediatric Leukemia
    9/21/2016 Objectives • Review newest therapies in pediatric oncology • Discuss the use of Blinatumomab in pediatric Update in Pediatric Oncology patients • Review Car T‐Cell immunotherapy in pediatric Katie Bruce, PharmD, BCPPS patients Pharmacy Clinical Specialist • Discuss the latest therapy approved for use in Pediatric Oncology and BMT The Children’s Hospital at TriStar neuroblastoma Centennial Disclosure • I have no financial conflicts to disclose Pediatric Leukemia Pediatric Leukemia Classification • Acute lymphoblastic leukemia (ALL) is the most • Over 85% of childhood ALL is B‐cell ALL common cancer in children ▫ Most commonly precursor‐B cell ALL ▫ Accounts for ~30% of all cancers 2% mature B‐cell ALL ▫ 3000 new cases in US each year ▫ 15% T‐cell ALL (Birth –21 years old) Investigating use of nelarabine and/or high dose methotrexate ~ 80% are ALL and ~20% are AML ▫ Incidence of 3.4 cases per 100,000 • Risk Criteria ▫ Most common between 2 and 5 years old ▫ Initial WBC count ▫ Boys > girls ▫ Age • Higher incidence in Caucasians and Hispanics vs. African ▫ Cytogenetics American Children ▫ Immunologic subtype www.curesearch.org www.curesearch.org 1 9/21/2016 Risk Stratification Outcomes • ~85% overall 5‐year event‐free survival ▫ 90 –95 % in low‐ or standard‐risk pre‐B ALL with good response to induction chemotherapy ▫ 75 –85 % in high‐risk with good early response ▫ <75% in very high‐risk (Ph+, hypodiploid, CNS3) or slow response to chemo • T‐cell ALL survival lower at 70 –75 % • Infant ALL ▫ Poor prognosis with 10‐30% event‐free
    [Show full text]
  • Qarziba, INN-Dinutuximab Beta
    ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions. 1. NAME OF THE MEDICINAL PRODUCT Qarziba 4.5 mg/mL concentrate for solution for infusion 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 1 mL of concentrate contains 4.5 mg dinutuximab beta. Each vial contains 20 mg dinutuximab beta in 4.5 mL. Dinutuximab beta is a mouse-human chimeric monoclonal IgG1 antibody produced in a mammalian cell line (CHO) by recombinant DNA technology. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Concentrate for solution for infusion Clear, colourless liquid. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Qarziba is indicated for the treatment of high-risk neuroblastoma in patients aged 12 months and above, who have previously received induction chemotherapy and achieved at least a partial response, followed by myeloablative therapy and stem cell transplantation, as well as patients with history of relapsed or refractory neuroblastoma, with or without residual disease. Prior to the treatment of relapsed neuroblastoma, any actively progressing disease should be stabilised by other suitable measures. In patients with a history of relapsed/refractory disease and in patients who have not achieved a complete response after first line therapy, Qarziba should be combined with interleukin-2 (IL-2). 4.2 Posology and method of administration Qarziba is restricted to hospital-use only and must be administered under the supervision of a physician experienced in the use of oncological therapies.
    [Show full text]
  • CDER Breakthrough Therapy Designation Approvals Data As of December 31, 2020 Total of 190 Approvals
    CDER Breakthrough Therapy Designation Approvals Data as of December 31, 2020 Total of 190 Approvals Submission Application Type and Proprietary Approval Use Number Number Name Established Name Applicant Date Treatment of patients with previously BLA 125486 ORIGINAL-1 GAZYVA OBINUTUZUMAB GENENTECH INC 01-Nov-2013 untreated chronic lymphocytic leukemia in combination with chlorambucil Treatment of patients with mantle cell NDA 205552 ORIGINAL-1 IMBRUVICA IBRUTINIB PHARMACYCLICS LLC 13-Nov-2013 lymphoma (MCL) Treatment of chronic hepatitis C NDA 204671 ORIGINAL-1 SOVALDI SOFOSBUVIR GILEAD SCIENCES INC 06-Dec-2013 infection Treatment of cystic fibrosis patients age VERTEX PHARMACEUTICALS NDA 203188 SUPPLEMENT-4 KALYDECO IVACAFTOR 21-Feb-2014 6 years and older who have mutations INC in the CFTR gene Treatment of previously untreated NOVARTIS patients with chronic lymphocytic BLA 125326 SUPPLEMENT-60 ARZERRA OFATUMUMAB PHARMACEUTICALS 17-Apr-2014 leukemia (CLL) for whom fludarabine- CORPORATION based therapy is considered inappropriate Treatment of patients with anaplastic NOVARTIS lymphoma kinase (ALK)-positive NDA 205755 ORIGINAL-1 ZYKADIA CERITINIB 29-Apr-2014 PHARMACEUTICALS CORP metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib Treatment of relapsed chronic lymphocytic leukemia (CLL), in combination with rituximab, in patients NDA 206545 ORIGINAL-1 ZYDELIG IDELALISIB GILEAD SCIENCES INC 23-Jul-2014 for whom rituximab alone would be considered appropriate therapy due to other co-morbidities
    [Show full text]
  • 5.01.582 Antibody-Drug Conjugates
    MEDICAL POLICY – 5.01.582 Antibody-Drug Conjugates Effective Date: June 1, 2021 RELATED MEDICAL POLICIES: Last Revised: May 11, 2021 None Replaces: N/A Select a hyperlink below to be directed to that section. POLICY CRITERIA | CODING | RELATED INFORMATION EVIDENCE REVIEW | REFERENCES | HISTORY ∞ Clicking this icon returns you to the hyperlinks menu above. Introduction An antibody is a blood protein. When the immune system detects an unhealthy cell, antibodies link to a molecule, known as an antigen, on the unhealthy cell. Monoclonal antibodies are produced in a laboratory. They are made to link to antigens usually found in high numbers on cancer cells. Antibody-drug conjugates combine monoclonal antibodies with certain chemotherapy drugs. The monoclonal antibodies find the cancer cells and the chemotherapy drug is released directly into those cells. The goal with this treatment is to target only cancer cells and spare nearby healthy cells. This policy describes when specific antibody-drug conjugates may be considered medically necessary. Note: The Introduction section is for your general knowledge and is not to be taken as policy coverage criteria. The rest of the policy uses specific words and concepts familiar to medical professionals. It is intended for providers. A provider can be a person, such as a doctor, nurse, psychologist, or dentist. A provider also can be a place where medical care is given, like a hospital, clinic, or lab. This policy informs them about when a service may be covered. Policy Coverage Criteria Drug Medical
    [Show full text]
  • A Novel Therapy for Lymphoma Using T-Cell Bispecific Antibodies Ajay Prakash1 and Catherine S
    Author Manuscript Published OnlineFirst on June 8, 2018; DOI: 10.1158/1078-0432.CCR-18-1363 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Immunity War: A Novel Therapy for Lymphoma Using T-cell Bispecific Antibodies Ajay Prakash1 and Catherine S. Diefenbach1 1. NYU Perlmutter Cancer Center, Department of Hematology-Oncology Corresponding Author: Catherine Diefenbach; NYU Perlmutter Cancer Center; 240 East 38th Street, 19th Floor, NY NY 10016; 212 731-5670; email: [email protected] Disclosures: CD: Research funding, Consulting Genentech Running title: A Novel Lymphoma Therapy Using T-cell Bispecific Antibodies Summary The activity of T cell mediated immunotherapies in B cell lymphoma has been limited to date. The novel bispecific antibody CD20-TCB, has a 2:1 antibody design to maximize T cell engagement, and demonstrates activity in preclinical models. This may represent a novel therapeutic approach for patients with relapsed/refractory NHL. Main Text In this issue of Clinical Cancer Research, Bacac and colleagues investigate the pre-clinical efficacy of a bispecific antibody in the treatment of lymphoma (1). To date, immunotherapy for the treatment of non-Hodgkin lymphoma (NHL) has been primarily focused on monoclonal antibody therapy, which has demonstrated both single agent activity and substantial synergy with cytotoxic chemotherapy (2). Further development of immunotherapy has been mixed. Chimeric antigen (CAR) T-cell therapy has demonstrated exciting activity with significant potential toxicities, and some preliminary successes have been seen with antibody drug conjugates. However, checkpoint blockade and other novel approaches have been complicated by disappointing activity as well as off-target side effects.
    [Show full text]